Sodium valproate (CAS number: 1069-66-5) is a broad-spectrum antiepileptic drug that is effective for various types of epilepsy. The main ingredient of sodium valproate concentrated solution for injection is sodium valproate, which was developed by Desitin Arzneimittel GmbH and marketed in European countries.
Factory Address: Wenhua Road, Zhifang street,Jiangxia district, Wuhan City, Hubei, China
Main products: Pharmaceutical intermediates
Contact number: +86 27-81302411
E-MAIL：sales@dkybpc.com
Factory Address: Room 1007, Area S, 1st, Building 3, No. 715, Yingshun Road, Shanghai, China
Main products: Chemical Products
Contact number: +86 021-65216239
E-MAIL: zhmx@shshenxia.com
Factory Address: Room 10-3, 12th Floor, Building A-3, National Geospatial Information Industry Base II (Phase 6), No. 3, Wuhan
Main products: Pharmaceutical raw materials
Contact number: +86 13163388153
E-MAIL: yeqiu416@163.com
Factory Address: No. 288, Qinhuai Avenue, Yongyang Street, Lishui District, Nanjing
Main products: Natural medicinal plant active ingredients
Contact number: +86 18266960953
E-MAIL: 907697096@qq.com
Fuyuan Pharmaceutical (601089) announced on the evening of June 13 that the company recently received the "Notice of Approval of Chemical API Marketing Application" for sodium valproate API approved and issued by the State Food and Drug Administration. Obtaining the approval of this application will enrich the company's product line and help the company develop continuously, stably and healthily.
China Resources Double-Crane Pharmaceutical Co.,Ltd. announced on the evening of March 25 that its wholly-owned subsidiary Shuanghe Limin recently received the drug registration certificate for sodium valproate injection concentrated solution issued by the State Food and Drug Administration. Sodium valproate injection concentrated solution is an anti-epileptic drug used to treat various types of epileptic diseases.